AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) . Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain .

Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine

Oxford Biomedica PLC (LON:OXB), a key manufacturer of what is known as the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled revenue expectations. The pair signed an 18-month supply agreement in September 2020.

Oxford Biomedica doubles financial guidance after AstraZeneca increases COVID-19 vaccine production

Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca after the drugmaker commissioned more batches from the company in the second half of 2021.

Oxford Biomedica lifts outlook as AstraZeneca ramps up vaccine output

The country said it has identified 26 suspected cases of bleeding and clotting among recipients of the vaccine.

India Reports ‘Minuscule' Risk Of Blood Clotting After AstraZeneca Vaccine

AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin) to treat hospitalized COVID-19 patients who are at risk of developing serious complications. The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status at 30 days.

AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study

Pfizer

Adverse reactions were short-lived, with no other safety concerns, the researchers say.

Mixing Pfizer and AstraZeneca Vaccines Increases Mild Side Effects but Is Safe, Study Shows

Mixing doses of COVID-19 vaccines increases the risk of mild to moderate side effects when compared with administering two shots of the same vaccine, according to a U.K. trial.

Mixing Pfizer and AstraZeneca COVID-19 vaccines increases mild side effects but is safe, study shows

JD.com

Hyper-growth stocks can help many people achieve their rich retirement goals. That's assuming you focus on safety and quality first, and prudent valuation and risk management always.

2 Hyper-Growth Blue Chips For A Rich Retirement

The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc's (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources quoted by Bloomberg. The rethink comes shortly before the first data from the treatment's trials that are expected in the coming weeks.

UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg

The European Union has reportedly launched a new lawsuit against AstraZeneca plc (NASDAQ: AZN) that could lead to financial sanctions for the company, which the E.U. alleges has breached a supply contract for COVID-19 vaccines.

European Union Announce Second Lawsuit Against AstraZeneca Over Delayed COVID-19 Vaccine Supply: Reuters

Pascal Soriot has been in charge of AstraZeneca since 2012, and resisted a takeover attempt by rival Pfizer in 2014.

AstraZeneca CEO Pascal Soriot narrowly wins vote on pay raise

AstraZeneca PLC's (LON:AZN) remuneration package for chief executive Pascal Soriot has been just about approved on Tuesday's annual general meeting. Nearly 40% of shareholders voted against it, with 60% voting in favour.

AstraZeneca boss to receive pay hike but 40% shareholders vote against it

AstraZeneca investors on Tuesday approved Chief Executive Pascal Soriot's pay package proposal by a narrow margin, after advisory groups said the rewards were excessive.

AstraZeneca shareholders narrowly approve CEO pay package

BioNTech SE

Johnson & Johnson

Moderna

Novavax

The government is having issues with giving away its excess supply.

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?

The European Union hasn't made any new orders for AstraZeneca's COVID-19 vaccine beyond June, when the contract ends, said European internal market commissioner Thierry Breton.

EU won't renew AstraZeneca COVID-19 vaccine; Pfizer shot will take precedence

The Investment Association, an influential investors group from the City of London, has come out against the proposed annual pay package of AstraZeneca Chief Executive Pascal Soriot, which could potentially net him some $25 million.

AstraZeneca CEO's pay package contested by investors

Amgen

THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

A number of investor advisory groups have called on AstraZeneca shareholders to oppose plans to increase Chief Executive Pascal Soriot's pay package when the COVID-19 vaccine maker holds its annual meeting on Tuesday.

AstraZeneca plan to beef up CEO Soriot's pay packet faces scrutiny at AGM

Norway should exclude the COVID-19 vaccines made by AstraZeneca and Johnson & Johnson from its immunization program, due to a small risk of rare but serious side effects, a panel of health experts commissioned by the government said on Monday. However, the panel said those shots should be available for people on a voluntary basis.

Norway may drop AstraZeneca, J&J vaccines; EU will not take AstraZeneca one after June

AstraZeneca PLC (LON:AZN) is facing investor backlash after proposing to boost the performance-related bonus to its chief executive by £2.3mln. If it goes ahead, Pascal Soriot would pocket awards of £12mln or more if the share price rises, with a total salary well over the £15.4mln he received last year.

AstraZeneca faces investor backlash after hiking chief executive bonus by £2.3mln

Daiichi Sankyo Co Ltd

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer. The ADC, datopotamab deruxtecan, posted a 43% response rate and five confirmed complete or partial responses among 21 patients with triple-negative breast cancer, according to cohort data from the TROPION-PanTumor01 Phase 1 study presented at the virtual ESMO Breast annual meeting 2021.

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer

Neighboring Denmark has already dropped both shots from its vaccination campaign.

Expert Panel Calls On Norway To Ditch AstraZeneca And Johnson & Johnson Covid Vaccines Over Blood Clot Risks

Sanofi

The companies have a promising RSV candidate.

Could AstraZeneca and Sanofi Win Big in RSV?

European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, raising new questions about potential side effects of the shot. What Happened: As part of a regular review of safety reports for the vaccine, the safety committee of EMA is analyzing data provided by AstraZeneca on cases of Guillain-Barre syndrome (GBS).

EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots

A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC). A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.

News for AstraZeneca Stock (AZN)